2Kawasaki M,Kuwano K,Nakanishi Y,et al.Analysis of Fas and Fas ligand expression and function in lung cancer cell lines[J].Eur J Cancer,2000,36 (5):656.
3Sikora J,Slodkowska J,Radomyski A,et al.Immuno histochemical evaluation of tumor angiogenesis in adenocarcinoma and squamous cell carcinoma of lung[J].Rocz Akad Med Bialymst,1997,42(Suppl 1):271.
4Shiraki K,Tsuji N,Shioda T,et al.Expression of Fas ligand in liver metastases of human colonic adenocarcinomas[J].Proc Natl Acad Sci USA,1997,94 (12):6420.
5Mountain CF.Revisions in the international system for staging lung cancer[J].Chest,1997,111 (6):1710.
6Bennett MW,O Connell J,O Sullivan GC,et al.The Fas counterattack in vivo:apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma[J].J Immunol,1998,160 (11):5669.
7Nagata S,Golstein P.The Fas death factor[J].Science,1995,267(5203):1449.
8Lenardo M,Chan MK,Homung F,et al.Mature T lymphocyte apoptosis-immune regulation in dynamic and unpredictable antigenic environment[J].Annu Rev Immunol,1999,17(1):221.
9Berke G.The CTL's kiss of death[J].Cell,1995,81(1):9.
10Chen JJ,Sun Y,Nabel GJ.Regulation of the proinflammatory effects of Fas ligand (CD95L)[J].Science,1998,282 (5394):1714.
